PrognomiQ announced the initial launch of its ProVue blood test while Mercy presented new data detailing the performance of its Halo lung cancer test.

The firm's new strategy revolves around adding to its test menu in an impactful way and expanding its installed base of instruments.

NEW YORK – Gradientech announced Wednesday that it has submitted a 510(k) premarket notification to the US Food and Drug Administration for its QuickMIC antimicrobial susceptibility testing platform.

The test is intended for patients with moderate to severe depression and differentiates between unipolar and bipolar depression.

Exact Sciences shareholders will receive $105 per common share as part of the deal, which is expected to close in the second quarter of 2026.

The company presented data at last week's AMP annual meeting proving the concept of its platform's applications in infectious disease and cancer.

At the AMP annual meeting, the UK-based company launched 300 assays to bring its total test menu to more than 900 en route to its goal of eventually offering a "test for everything." ...

A slew of new studies and reports suggest that new molecular approaches may soon help reduce the global burden of tuberculosis.

With the transaction, which Bloomberg News said could be announced within the next several days, Abbott would acquire tests including Exact's Cologuard, among other tests.

The test, which runs on the BD Viper LT and BD Cor automated PCR systems, will be added to the WHO's list of prequalified IVDs for cervical cancer screening.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...